Loading...
The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against sup...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Landes Bioscience
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3881106/ https://ncbi.nlm.nih.gov/pubmed/24404422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.25997 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|